Friday was a good day for Gilead Sciences (GILD - Get Report). Not only did it win U.S. marketing approval late Friday for a new drug to treat a life-threatening lung disease, but the drug's FDA-approved label should also give the company an advantage over its competition.The drug, ambrisentan, which will now go by the brand name Letairis, will be used to treat pulmonary arterial hypertension (PAH), a chronic disease caused by constriction of the blood vessels that bring blood from the heart to the lungs. The disease affects about 200,000 patients worldwide.
Good Tidings for Gilead
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.